A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

NCT06733935 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis
Idiopathic Inflammatory Myopathies
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Interventions

DRUG: NKX019
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Nkarta, Inc.